XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its
second quarter financial results on August 5, 2009 at approximately 4:30
p.m. Eastern Time. The company will host a conference call at 5:00 p.m.
Eastern Time that same day. A replay of the call will be available for
one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com.
Please join the call at least 15 minutes prior to the start to ensure
time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514.
International callers may access the live call by dialing 706-679-1417.
The reference number to enter the call is 13770917.
The replay of the conference call may be accessed that same day after
8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com,
or via phone at 1-800-642-1687 for domestic callers, or 706-645-9291 for
international callers. The reference number to enter the replay of the
call is 13770917.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a
portfolio of internally discovered product candidates that utilize the
body’s natural nutrient transport mechanisms to improve the therapeutic
benefits of existing drugs. XenoPort is developing its lead product
candidate, XP13512, in collaboration with Astellas Pharma Inc. and
GlaxoSmithKline (GSK). The Food and Drug Administration is currently
reviewing GSK’s NDA for XP13512 as a potential treatment for
moderate-to-severe primary restless legs syndrome in the United States.
XenoPort’s product candidates are also being studied for the potential
treatment of gastroesophageal reflux disease, migraine headaches,
neuropathic pain, spasticity related to spinal cord injury, acute back
spasms and Parkinson’s disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered trademark of XenoPort, Inc.
XNPT2F
XenoPort, Inc.
Jackie Cossmon, 408-616-7295
ir@XenoPort.com
